Haploidentical, unmanipulated G-CSF-primed peripheral blood stem cell transplantation for high-risk hematologic malignancies: an update.
Emerging data demonstrate promising results of related haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HCT) for the treatment of hematologic malignancies. Data about G-CSF primed PBSC as reliable source of graft with myeloablative conditioning are lacking. We updated the outcomes in 130 adult patients with high-risk hematologic malignancies who received haplo-PBSC transplantation consecutively under busulfan-based conditioning. PBSC were freshly isolated and infused without ex vivo T-cell depletion into the recipients. Myeloid recovery was achieved in 99.2% patients with full donor chimerism. The cumulative incidence of acute grade 3-4 GvHD, overall and extensive chronic GvHD was 14.9%, 38.6% and 16.5%, respectively. The 3-year non-relapse mortality rate was 24.1%. Non-remission prior to transplant was associated with higher incidence of relapse (P=0.006), inferior overall survival (P=0.017) and leukemia-free survival (P=0.024). These data suggest that PBSC is a reliable graft source in haploidentical, unmanipulated transplant settings under myeloablative conditioning in patients with high-risk hematologic malignancies.
Department of Hematology, Chinese PLA General Hospital, Beijing, China.
W-R
WR
Huang
Department of Hematology, Chinese PLA General Hospital, Beijing, China.
H-H
HH
Li
Department of Hematology, Chinese PLA General Hospital, Beijing, China.
C-J
CJ
Gao
Department of Hematology, Chinese PLA General Hospital, Beijing, China.
J
J
Bo
Department of Hematology, Chinese PLA General Hospital, Beijing, China.
F
F
Li
Department of Hematology, Chinese PLA General Hospital, Beijing, China.
L-P
LP
Dou
Department of Hematology, Chinese PLA General Hospital, Beijing, China.
L-L
LL
Wang
Department of Hematology, Chinese PLA General Hospital, Beijing, China.
Y
Y
Jing
Department of Hematology, Chinese PLA General Hospital, Beijing, China.
L
L
Wang
Department of Hematology, Chinese PLA General Hospital, Beijing, China.
D-H
DH
Liu
Department of Hematology, Chinese PLA General Hospital, Beijing, China.
L
L
Yu
D000293:Adolescent; D000328:Adult; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D046528:Chimerism; D005260:Female; D006086:Graft vs Host Disease; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D018570:Risk Assessment; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods; D000075442:Transplantation, Haploidentical / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D016896:Treatment Outcome; D055815:Young Adult
D019653:Myeloablative Agonists; D016179:Granulocyte Colony-Stimulating Factor; D002066:Busulfan